Artificial Intelligence Predicts Overall Survival in Patients With Advanced Melanoma

Source: Cancer Network, May 2022

By reading CT scans, machine learning could aid investigators in improving treatment decision making.

Radiomics and machine learning can help estimate overall survival (OS) in patients with unresectable melanoma, potentially improving clinical decision-making, according to study findings published in JAMA Oncology.

A team of investigators from various institutions on the East Coast analyzed data from 2 large multicenter clinical trials that included patients with advanced melanoma who received treatment with immunotherapy. Using an area under the time-dependent receiver operating characteristics curve (AUC), the radiomics signature reached an AUC for estimation of OS status of 0.92 (95% CI, 0.89-0.95) compared with 0.80 (95% CI, 0.75-0.84) with RECIST 1.1 at month 3. Furthermore, the radiomics signature was divided into 3 parts, ranging from best to worst estimated prognosis—complete or partial response (32.4%), stable